Skip to main content

Need for Pretransplant Midodrine Does Not Negatively Impact Simultaneous Liver-kidney Transplant Outcomes.

Publication ,  Journal Article
Barman, PM; King, LY; Berg, CL; Parish, A; Niedzwiecki, D; Barbas, AS; McElroy, L; Patel, YA
Published in: Transplant Direct
January 2021

BACKGROUND: Midodrine is often needed pretransplant to improve hemodynamics in simultaneous liver-kidney transplant candidates. Previous research has shown that patients requiring midodrine before kidney transplant alone have increased posttransplant risk for delayed allograft function, graft failure, and death. However, the impact of pretransplant midodrine use on outcomes after simultaneous liver-kidney transplant is unknown. METHODS: We performed a retrospective study of all adult (age ≥18 y) simultaneous liver-kidney transplant recipients from a single academic transplant center from February 1, 2002, to June 30, 2019. RESULTS: Sixty-four simultaneous liver-kidney transplants were performed in our institution during this time period, of which, 43 were not on midodrine before transplant, 17 were on midodrine alone, and 4 were on intravenous (IV) vasopressor therapy. Despite the midodrine group having a higher MELD-Na at listing, higher MELD-Na at transplant, and being older, there were no significant differences in key outcomes including delayed renal allograft function, estimated glomerular filtration rate at transplant discharge, and estimated glomerular filtration rate at 1 y after transplant compared with the nonmidodrine group. There was no significant difference in graft failure or survival at last follow-up. CONCLUSIONS: Our study suggests that need for pretransplant midodrine should not be a barrier to simultaneous liver-kidney transplant.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Transplant Direct

DOI

ISSN

2373-8731

Publication Date

January 2021

Volume

7

Issue

1

Start / End Page

e640

Location

United States

Related Subject Headings

  • 3204 Immunology
  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Barman, P. M., King, L. Y., Berg, C. L., Parish, A., Niedzwiecki, D., Barbas, A. S., … Patel, Y. A. (2021). Need for Pretransplant Midodrine Does Not Negatively Impact Simultaneous Liver-kidney Transplant Outcomes. Transplant Direct, 7(1), e640. https://doi.org/10.1097/TXD.0000000000001071
Barman, Pranab M., Lindsay Y. King, Carl L. Berg, Alice Parish, Donna Niedzwiecki, Andrew S. Barbas, Lisa McElroy, and Yuval A. Patel. “Need for Pretransplant Midodrine Does Not Negatively Impact Simultaneous Liver-kidney Transplant Outcomes.Transplant Direct 7, no. 1 (January 2021): e640. https://doi.org/10.1097/TXD.0000000000001071.
Barman PM, King LY, Berg CL, Parish A, Niedzwiecki D, Barbas AS, et al. Need for Pretransplant Midodrine Does Not Negatively Impact Simultaneous Liver-kidney Transplant Outcomes. Transplant Direct. 2021 Jan;7(1):e640.
Barman, Pranab M., et al. “Need for Pretransplant Midodrine Does Not Negatively Impact Simultaneous Liver-kidney Transplant Outcomes.Transplant Direct, vol. 7, no. 1, Jan. 2021, p. e640. Pubmed, doi:10.1097/TXD.0000000000001071.
Barman PM, King LY, Berg CL, Parish A, Niedzwiecki D, Barbas AS, McElroy L, Patel YA. Need for Pretransplant Midodrine Does Not Negatively Impact Simultaneous Liver-kidney Transplant Outcomes. Transplant Direct. 2021 Jan;7(1):e640.

Published In

Transplant Direct

DOI

ISSN

2373-8731

Publication Date

January 2021

Volume

7

Issue

1

Start / End Page

e640

Location

United States

Related Subject Headings

  • 3204 Immunology
  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology